Vaxcyte Analyst Price Targets - Benzinga

Vaxcyte Inc

PCVXNASDAQ

Trade with Public

Trade with Public

$61.46

0.791.3%

Últ. Act.: Oct 28, 6:29 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Vaxcyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vaxcyte (PCVX).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$122Upside to Avg. PT+100.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$120
Oct 5, 2026	BTIG	Thomas Shrader	Maintained	Buy	$89
Oct 5, 2026	Needham	Joseph Stringer	PT Raise	Buy	$110→$122
Oct 5, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$116→$125
Sep 28, 2026	B of A Securities	Jason Gerberry	PT Cut	Buy	$133→$130
Sep 25, 2026	Needham	Joseph Stringer	Maintained	Buy	$110
Feb 26, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$85→$89
Feb 2, 2026	Guggenheim	Seamus Fernandez	Maintained	Buy	$116
Jan 7, 2026	Needham	Joseph Stringer	PT Raise	Buy	$90→$110
Nov 10, 2025	BTIG	Thomas Shrader	Maintained	Buy	$85
Oct 16, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$160→$85
Sep 12, 2025	Goldman Sachs	Asad Haider	Initiate	Neutral	$38
Apr 22, 2025	Cantor Fitzgerald	Carter Gould	Initiate	Overweight	—
Apr 8, 2025	Needham	Joseph Stringer	Maintained	Buy	$90
Apr 1, 2025	Goldman Sachs	Chris Shibutani	PT Cut	Buy	$138→$100
Apr 1, 2025	B of A Securities	Jason Gerberry	PT Cut	Buy	$157→$137
Apr 1, 2025	Needham	Joseph Stringer	PT Cut	Buy	$140→$90
Mar 12, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	$160
Feb 26, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	$160
Feb 26, 2025	Needham	Joseph Stringer	Maintained	Buy	$140

Analyst Ratings News

PRO
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target

BTIG analyst Thomas Shrader reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $89 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Vaxcyte, Raises Price Target to $122

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $110 to $122.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125

Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130

B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Target

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $110 price target.

Benzinga Newsdesk